Despite Shanghai Labway Clinical Laboratory's strong revenue...
Despite Shanghai Labway Clinical Laboratory's strong revenue growth, investors may be skeptical about its ability to maintain recent growth rates, potentially pressuring the P/S ratio. The risk of a price decline seems low, but future revenue fluctuations are a concern for investors.
Investors Give Shanghai Labway Clinical Laboratory Co., Ltd (SZSE:301060) Shares A 27% Hiding
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment